Estrella Immunopharma Inc., a clinical stage biopharmaceutical company, has announced the initiation of the second cohort in its Phase I/II STARLIGHT-1 trial for the CD19-redirected ARTEMIS® T-cell therapy, EB103. The trial focuses on treating patients with Advanced B-Cell Non-Hodgkin's Lymphomas. The first patient in this second cohort has already been dosed, marking a significant milestone in the study's progression. The second cohort will assess EB103 at a higher dose level following a review of safety data from the first cohort, which reported no dose-limiting toxicities or treatment-related serious adverse events. This development is part of Estrella's ongoing efforts to complete the Phase I stage of the STARLIGHT-1 trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.